The cost effectiveness of the SIMPle intervention to improve antimicrobial prescribing for urinary tract infection in primary care

J Public Health (Oxf). 2017 Dec 1;39(4):e282-e289. doi: 10.1093/pubmed/fdw102.

Abstract

Background: Antimicrobial resistance is a major public health issue. This study examines the cost effectiveness of the SIMPle (Supporting the Improvement and Management of Prescribing for Urinary Tract Infections (UTI)) intervention to improve antimicrobial prescribing in primary care in Ireland.

Methods: An economic evaluation was conducted alongside a cluster randomized controlled trial of 30 general practices and 2560 patients with a diagnosis of UTI. Practices were randomized to the usual practice control or the SIMPle intervention (arm A or B). Data at 6 months follow-up were used to estimate incremental costs, incremental effectiveness in terms of first-line antimicrobial prescribing for UTI and cost effectiveness acceptability curves.

Results: The SIMPle intervention was, on average, more costly and more effective than the control. The probability of intervention arm A being cost effective was 0.280, 0.995 and 1.000 at threshold values of €50, €150 and €250 per percentage point increase in first-line antimicrobial prescribing respectively. The equivalent probabilities for intervention arm B were 0.121, 0.863 and 0.985, respectively.

Conclusions: The cost effectiveness of the SIMPle intervention depends on the value placed on improving antimicrobial prescribing. Future studies should examine the wider and longer term costs and outcomes of improving antimicrobial prescribing.

Keywords: economics; primary care; public health.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / economics*
  • Anti-Bacterial Agents / therapeutic use*
  • Cost-Benefit Analysis
  • Drug Utilization
  • Humans
  • Inappropriate Prescribing / prevention & control*
  • Ireland
  • Prescription Drug Overuse / prevention & control
  • Primary Health Care
  • Urinary Tract Infections / drug therapy*
  • Urinary Tract Infections / economics*

Substances

  • Anti-Bacterial Agents